Many of these studies used liquid biopsy powered by the ddPCR platform to measure circulating tumor DNA (ctDNA) and evaluate ctDNA’s potential as a biomarker for guiding cancer treatment decisions and predicting efficacy.
Detecting and analyzing ctDNA in liquid biopsy samples is gaining recognition as a less invasive method of monitoring disease progression. Researchers are not only testing known mutations in various cancers but are also discovering new mutations that may become important biomarkers. However, wider clinical adoption requires that these ctDNA biomarkers be tested in various cancers and clinical conditions. The studies below highlight efforts to evaluate ctDNA as a potential biomarker vehicle to monitor treatment efficacy, tumor progression, or tumor recurrence.
Mutant BRAF ctDNA is a potential biomarker for advanced melanoma treatment efficacy
There are currently no validated blood-based biomarkers for monitoring treatment efficacy in patients with advanced melanoma. David Polsky, MD, PhD, of NYU Langone Medical Center, ...
